Citigroup initiated coverage on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research note issued to investors on Friday, January 5th, Marketbeat Ratings reports. The firm issued a buy rating and a $40.00 price objective on the biotechnology company’s stock.
Several other research analysts have also recently issued reports on the stock. BidaskClub upgraded shares of CytomX Therapeutics from a hold rating to a buy rating in a report on Friday, December 15th. ValuEngine lowered shares of CytomX Therapeutics from a hold rating to a sell rating in a research note on Friday, December 1st. Zacks Investment Research lowered shares of CytomX Therapeutics from a buy rating to a hold rating in a research note on Friday, November 10th. Cantor Fitzgerald initiated coverage on shares of CytomX Therapeutics in a research note on Monday, October 23rd. They set an overweight rating and a $35.00 target price for the company. Finally, Cowen reissued an outperform rating on shares of CytomX Therapeutics in a research note on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. CytomX Therapeutics presently has a consensus rating of Buy and a consensus target price of $32.78.
Shares of CytomX Therapeutics (NASDAQ:CTMX) opened at $25.17 on Friday. CytomX Therapeutics has a 1 year low of $11.06 and a 1 year high of $25.60. The firm has a market cap of $966.74, a PE ratio of -15.83 and a beta of 0.47.
In other news, CEO Sean A. Mccarthy sold 14,342 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $19.86, for a total transaction of $284,832.12. Following the transaction, the chief executive officer now owns 18,587 shares in the company, valued at approximately $369,137.82. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Debanjan Ray sold 2,500 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $20.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now owns 12,126 shares in the company, valued at approximately $242,520. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,760 shares of company stock valued at $1,533,840. 8.00% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Macquarie Group Ltd. acquired a new position in shares of CytomX Therapeutics during the 3rd quarter worth $107,000. Legal & General Group Plc grew its stake in CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in CytomX Therapeutics in the 2nd quarter valued at $174,000. Voya Investment Management LLC acquired a new position in CytomX Therapeutics in the 2nd quarter valued at $203,000. Finally, Nationwide Fund Advisors grew its stake in CytomX Therapeutics by 39.4% in the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 4,622 shares during the last quarter. Institutional investors own 63.13% of the company’s stock.
TRADEMARK VIOLATION WARNING: “CytomX Therapeutics (CTMX) Coverage Initiated at Citigroup” was first posted by BBNS and is owned by of BBNS. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/cytomx-therapeutics-ctmx-research-coverage-started-at-citigroup/1819535.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with our FREE daily email newsletter.